ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

How I Manage Patients with Frequent PVCs

Stanford Medicine

R. John

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Rhythm vs Rate: Has the Tide Changed Since the AFFIRM Trial?

The Texas Heart Institute

M. Razavi

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Top 5 Arrhythmias You Need to Know

Joel Gorfinkel

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

HFpEF in Women

Scripps Health

B. Borlaug

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Postural Tachycardia Syndrome: Pathophysiology and Impact of Tragus …

Virtual EP Connect

V. Reddy, F. Marchlinski, T. Glotzer, B. Olshansky, S. Po, S. Stavrakis

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money